Altai Protocol Library
1041 protocols and counting
All protocols with references and links
All protocols reviewed by a Medical Oncologist/Hematologist
All protocols in major guidelines included
Ability to create your own protocols
New Indication: Trastuzumab Deruxtecan in HER2-Mutant Non–Small-Cell Lung Cancer
Study: Multicenter, international, phase 2 study Metastatic HER2-mutant NSCLC, refractory to standard treatment Trastuzumab deruxtecan (N=91) Efficacy: mPFS: 8.2 mos, mOS:17.8 mos mDOR: 9.3 mos Safety: All patients had adverse
New Reference: Ribociclib plus Letrozole in Advanced Breast Cancer
Study: Randomized phase III trial (MONALEESA-2) Postmenopausal, HR-positive, HER2-negative recurrent or metastatic breast cancer with no previous systemic therapy for advanced disease Ribociclib or placebo in combination with letrozole Efficacy:
New Indication: Trastuzumab, Pertuzumab, and Docetaxel in Advanced her2+ Non–Small-Cell Lung Cancer
Study: Multicenter, nonrandomized phase II study HER2-mutated, advanced NSCLC with ≥ one previous line including platinums Pertuzumab+trastuzumab+docetaxel (n=45) Efficacy: ORR: 29%, SD: 58% mPFS: 6.8 mos, mOS: 17.6 mos 5
New Reference: DD-MVAC vs. GC in muscle-invasive bladder cancer
Study: Randomized phase II trial (GETUG-AFU V05 VESPER) Nonmetastatic muscle-invasive bladder cancer Dd-MVAC vs gemsitabin+cisplatin. Neoadjuvant OR adjuvant chemotherapy Efficacy: Organ confined response: 77% v 63% (p = 0.001) Neoadjuvant
New Protocol: Panitumumab + FU/FA for maintenance in colorectal cancer
Study: Open-label randomized trial (AIO KRK 0212) RAS Wild-type metastatic colorectal cancer Post first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab FU/FA plus Pmab or FU/FA
New Protocol: Panitumumab + FU/FA for maintenance in colorectal cancer
Study: Open-label randomized trial (AIO KRK 0212) RAS Wild-type metastatic colorectal cancer Post first-line induction therapy with six cycles of FU/FA and oxaliplatin plus Pmab FU/FA plus Pmab or FU/FA
New Drug: Cabozantinib for differentiated thyroid cancer
Study: Double-blind, randomized Phase III trial (COSMIC-311) RAI-refractory differentiated thyroid cancer pts with prior lenvatinib or sorafenib Cabozantinib 60 mg daily vs. placebo Efficacy: ORR: 18% vs. 0% Median PFS: